Copyright © 2011 Piotr Rutkowski et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

1. C. K. Chang, I. A. Jacobs, and G. I. Salti, “Outcomes of surgery for dermatofibrosarcoma protuberans,” European Journal of Surgical Oncology, vol. 30, no. 3, pp. 341–345, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
2. W. B. Laskin, “Dermatofibrosarcoma protuberans,” CA: A Cancer Journal for Clinicians, vol. 42, no. 2, pp. 116–125, 1992. View at Scopus
3. W. B. Bowne, C. R. Antonescu, D. H. Y. Leung et al., “Dermatofibrosarcoma protuberans: a clinicopathologic analysis of patients treated and followed at a single institution,” Cancer, vol. 88, no. 12, pp. 2711–2720, 2000. View at Publisher · View at Google Scholar · View at Scopus
4. T. Mentzel, A. Beham, D. Katenkamp, A. P. Dei Tos, and C. D. M. Fletcher, “Fibrosarcomatous (‘high-grade’) dermatofibrosarcoma protuberans: clinicopathologic and immunohistochemical study of a series of 41 cases with emphasis on prognostic significance,” American Journal of Surgical Pathology, vol. 22, no. 5, pp. 576–587, 1998. View at Publisher · View at Google Scholar · View at Scopus
5. P. Lal, R. Sharma, H. Mohan, and M. S. Sekhon, “Dermatofibrosarcoma protuberans metastasizing to lymph nodes: a case report and review of literature,” Journal of Surgical Oncology, vol. 72, no. 3, pp. 178–180, 1999. View at Publisher · View at Google Scholar · View at Scopus
6. C. Diaz-Cascajo, W. Weyers, L. Bornego, et al., “Dermatofibrosarcoma protuberans with fibrosarcomatous areas: a clinico-pathologic and immunohistochemical study four cases,” American Journal of Dermathopathology, vol. 19, pp. 562–567, 1997.
7. Z. Kimmel, D. Ratner, J. Y. S. Kim, J. D. Wayne, A. W. Rademaker, and M. Alam, “Peripheral excision margins for dermatofibrosarcoma protuberans: a meta-analysis of spatial data,” Annals of Surgical Oncology, vol. 14, no. 7, pp. 2113–2120, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
8. H. M. Gloster, K. R. Harris, and R. K. Roenigk, “A comparison between Mohs micrographic surgery and wide surgical excision for the treatment of dermatofibrosarcoma protuberans,” Journal of the American Academy of Dermatology, vol. 35, no. 1, pp. 82–87, 1996. View at Scopus
9. L. Barnes, J. A. Coleman Jr., and J. T. Johnson, “Dermatofibrosarcoma protuberans of the head and neck,” Archives of Otolaryngology, vol. 110, no. 6, pp. 398–404, 1984. View at Scopus
10. D. F. Roses, Q. Valensi, G. LaTrenta, and M. N. Harris, “Surgical treatment of dermatofibrosarcoma protuberans,” Surgery Gynecology and Obstetrics, vol. 162, no. 5, pp. 449–452, 1986. View at Scopus
11. E. J. Th. Rutgers E.J., B. B. R. Kroon, C. E. Albus-Lutter, and E. Gortzak, “Dermatofibrosarcoma protuberans: treatment and prognosis,” European Journal of Surgical Oncology, vol. 18, no. 3, pp. 241–248, 1992. View at Scopus
12. C. K. Koh, C. B. Ko, H. P. R. Bury, and E. H. Wyatt, “Dermatofibrosarcoma protuberans,” International Journal of Dermatology, vol. 34, no. 4, pp. 256–260, 1995. View at Scopus
13. A. Stojadinovic, H. M. Karpoff, C. R. Antonescu et al., “Dermatofibrosarcoma protuberans of mthe head and neck,” Annals of Surgical Oncology, vol. 7, no. 9, pp. 696–704, 2000. View at Scopus
14. S. T. Heuvel, A. Suurmeijer, E. Pras, R. J. Van Ginkel, and H. J. Hoekstra, “Dermatofibrosarcoma protuberans: recurrence is related to the adequacy of surgical margins,” European Journal of Surgical Oncology, vol. 36, no. 1, pp. 89–94, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
15. M. Fiore, R. Miceli, C. Mussi et al., “Dermatofibrosarcoma protuberans treated at a single institution: a surgical disease with a high cure rate,” Journal of Clinical Oncology, vol. 23, no. 30, pp. 7669–7675, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
16. D. DuBay, V. Cimmino, L. Lowe, T. M. Johnson, and V. K. Sondak, “Low recurrence rate after surgery for dermatofibrosarcoma protuberans: a multidisciplinary approach from a single institution,” Cancer, vol. 100, no. 5, pp. 1008–1016, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
17. J. M. Farma, J. B. Ammori, J. S. Zager et al., “Dermatofibrosarcoma protuberans: how wide should we resect?” Annals of Surgical Oncology, vol. 17, pp. 2112–2118, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
18. J. Wacker, B. Khan-Durani, and W. Hartschuh, “Modified mohs micrographic surgery in the therapy of dermatofibrosarcoma protuberans: analysis of 22 patients,” Annals of Surgical Oncology, vol. 11, no. 4, pp. 438–444, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
19. V. P. Khatri, J. M. Galante, R. J. Bold, P. D. Schneider, R. Ramsamooj, and J. E. Goodnight, “Dermatofibrosarcoma protuberans: reappraisal of wide local excision and impact of inadequate initial treatment,” Annals of Surgical Oncology, vol. 10, no. 9, pp. 1118–1122, 2003. View at Publisher · View at Google Scholar · View at Scopus
20. A. N. Meguerditchian, J. Wang, B. Lema, W. G. Kraybill, N. C. Zeitouni, and J. M. Kane, “Wide excision or Mohs micrographic surgery for the treatment of primary dermatofibrosarcoma protuberans,” American Journal of Clinical Oncology, vol. 33, no. 3, pp. 300–303, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
21. J. A. Bridge, J. R. Neff, and A. A. Sandberg, “Cytogenetic analysis of dermatofibrosarcoma protuberans,” Cancer Genetics and Cytogenetics, vol. 49, no. 2, pp. 199–202, 1990. View at Publisher · View at Google Scholar · View at Scopus
22. N. Mandahl, S. Heim, H. Willen, A. Rydholm, and F. Mitelman, “Supernumerary ring chromosome as the sole cytogenetic abnormality in a dermatofibrosarcoma protuberans,” Cancer Genetics and Cytogenetics, vol. 49, no. 2, pp. 273–275, 1990. View at Publisher · View at Google Scholar · View at Scopus
23. N. Mandahl, J. Limon, F. Mertens, K. Arheden, and F. Mitelman, “Ring marker containing 17q and chromosome 22 in a case of dermatofibrosarcoma protuberans,” Cancer Genetics and Cytogenetics, vol. 89, no. 1, pp. 88–91, 1996. View at Scopus
24. F. Pedeutour, J. M. Coindre, G. Sozzi et al., “Supernumerary ring chromosomes containing chromosome 17 sequences: a specific feature of dermatofibrosarcoma protuberans?” Cancer Genetics and Cytogenetics, vol. 76, no. 1, pp. 1–9, 1994. View at Scopus
25. F. Pedeutour, M. P. Simon, F. Minoletti et al., “Ring 22 chromosomes in dermatofibrosarcoma protuberans are low-level amplifiers of chromosome 17 and 22 sequences,” Cancer Research, vol. 55, no. 11, pp. 2400–2403, 1995. View at Scopus
26. F. Pedeutour, J. P. Lacour, C. Perrin et al., “Another case of t(17;22)(q22;q13) in an infantile dermatofibrosarcoma protuberans,” Cancer Genetics and Cytogenetics, vol. 89, no. 2, pp. 175–176, 1996. View at Publisher · View at Google Scholar · View at Scopus
27. F. Pedeutour, M. P. Simon, F. Minoletti et al., “Translocation, t(17;22)(q22;q13), in dermatofibrosarcoma protuberans: a new tumor-associated chromosome rearrangement,” Cytogenetics and Cell Genetics, vol. 72, no. 2-3, pp. 171–174, 1996. View at Scopus
28. S. Kiuru-Kuhlefelt, W. El-Rifai, J. Fanburg-Smith, J. Kere, M. Miettinen, and S. Knuutila, “Concomitant DNA copy number amplification at 17q and 22q in dermatofibrosarcoma protuberans,” Cytogenetics and Cell Genetics, vol. 92, no. 3-4, pp. 192–195, 2001. View at Scopus
29. S. C. Linn, R. B. West, J. R. Pollack et al., “Gene expression patterns and gene copy number changes in dermatofibrosarcoma protuberans,” American Journal of Pathology, vol. 163, no. 6, pp. 2383–2395, 2003. View at Scopus
30. A. A. Sandberg and J. A. Bridge, “Updates on the cytogenetics and molecular genetics of bone and soft tissue tumors: dermatofibrosarcoma protuberans and giant cell fibroblastoma,” Cancer Genetics and Cytogenetics, vol. 140, no. 1, pp. 1–12, 2003. View at Publisher · View at Google Scholar · View at Scopus
31. N. Sirvent, G. Maire, and F. Pedeutour, “Genetics of dermatofibrosarcoma protuberans family of tumors: from ring chromosomes to tyrosine kinase inhibitor treatment,” Genes Chromosomes and Cancer, vol. 37, no. 1, pp. 1–19, 2003. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
32. M. P. Simon, F. Pedeutour, N. Sirvent et al., “Deregulation of the platelet-derived growth factor B-chain gene via fusion with collagen gene COL1A1 in dermatofibrosarcoma protuberans and giant-cell fibroblastoma,” Nature Genetics, vol. 15, no. 1, pp. 95–98, 1997. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
33. A. Shimizu, K. P. O'Brien, T. Sjöblom et al., “The dermatofibrosarcoma protuberans-associated collagen type Iα1/platelet-derived growth factor (PDGF) B-chain fusion gene generates a transforming protein that is processed to functional PDGF-BB,” Cancer Research, vol. 59, no. 15, pp. 3719–3723, 1999. View at Scopus
34. M.-P. Simon, M. Navarro, D. Roux, et al., “Transforming properties of chimerical protein COL1A1-PDGFB generated by dermatofibrosarcoma protuberans-associated translocation t(17;22)(q22;q13.1),” Cancer Genetics and Cytogenetics, vol. 128, p. 82, 2001.
35. G. McArthur, “Molecularly targeted treatment for dermatofibrosarcoma protuberans,” Seminars in Oncology, vol. 31, no. 6, pp. 30–36, 2004. View at Publisher · View at Google Scholar · View at Scopus
36. A. Greco, L. Fusetti, R. Villa et al., “Transforming activity of the chimeric sequence formed by the fusion of collagen gene COL1A1 and the platelet derived growth factor b-chain gene in dermatofibrosarcoma protuberans,” Oncogene, vol. 17, no. 10, pp. 1313–1319, 1998. View at Scopus
37. A. Greco, E. Roccato, C. Miranda, L. Cleris, F. Formelli, and M. A. Pierotti, “Growth-inhibitory effect of STI571 on cells transformed by the COL1A1/PDGFB rearrangement,” International Journal of Cancer, vol. 92, no. 3, pp. 354–360, 2001. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
38. P. Dal Cin, R. Sciot, I. De Wever et al., “Cytogenetic and immunohistochemical evidence that giant cell fibroblastoma is related to dermatofibrosarcoma protuberans,” Genes Chromosomes and Cancer, vol. 15, no. 1, pp. 73–75, 1996. View at Publisher · View at Google Scholar · View at Scopus
39. K. P. O'Brien, E. Seroussi, P. Dal Cin et al., “Various regions within the alpha-helical domain of the COL1A1 gene are fused to the second exon of the PDGFB gene in dermatofibrosarcomas and giant- cell fibroblastomas,” Genes Chromosomes and Cancer, vol. 23, no. 2, pp. 187–193, 1998. View at Scopus
40. M. J. Terrier-Lacombe, L. Guillou, G. Maire et al., “Dermatofibrosarcoma protuberans, giant cell fibroblastoma, and hybrid lesions in children: clinicopathologic comparative analysis of 28 cases with molecular data—a study from the french federation of cancer centers sarcoma group,” American Journal of Surgical Pathology, vol. 27, no. 1, pp. 27–39, 2003. View at Publisher · View at Google Scholar · View at Scopus
41. R. S. Macarenco, R. Zamolyi, M. F. Franco et al., “Genomic gains of COLIAI-PDFGB occur in the histologic evolution of giant cell fibroblastoma into dermatofibrosarcoma protuberans,” Genes Chromosomes and Cancer, vol. 47, no. 3, pp. 260–265, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
42. J. J. Abbott, M. Erickson-Johnson, X. Wang, A. G. Nascimento, and A. M. Oliveira, “Gains of COL1A1-PDGFB genomic copies occur in fibrosarcomatous transformation of dermatofibrosarcoma protuberans,” Modern Pathology, vol. 19, no. 11, pp. 1512–1518, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
43. D. Kerob, F. Pedeutour, C. Leboeuf et al., “Value of cytogenetic analysis in the treatment of dermatofibrosarcoma protuberans,” Journal of Clinical Oncology, vol. 26, no. 10, pp. 1757–1759, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
44. J. Wang, Y. Morimitsu, S. Okamoto et al., “COL1A1-PDGFB fusion transcripts in fibrosarcomatous areas of six dermatofibrosarcomas protuberans,” Journal of Molecular Diagnostics, vol. 2, no. 1, pp. 47–52, 2000. View at Scopus
45. K. U. Patel, S. S. Szabo, V. S. Hernandez et al., “Dermatofibrosarcoma protuberans COL1A1-PDGFB fusion is identified in virtually all dermatofibrosarcoma protuberans cases when investigated by newly developed multiplex reverse transcription polymerase chain reaction and fluorescence in situ hybridization assays,” Human Pathology, vol. 39, no. 2, pp. 184–193, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
46. T. Sjöblom, A. Shimizu, K. P. O'Brien et al., “Growth inhibition of dermatofibrosarcoma protuberans tumors by the platelet-derived growth factor receptor antagonist STI571 through induction of apoptosis,” Cancer Research, vol. 61, no. 15, pp. 5778–5783, 2001. View at Scopus
47. R. G. Maki, R. A. Awan, R. H. Dixon, S. Jhanwar, and C. R. Antonescu, “Differential sensitivity to imatinib of 2 patients with metastatic sarcoma arising from dermatofibrosarcoma protuberans,” International Journal of Cancer, vol. 100, no. 6, pp. 623–626, 2002. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
48. B. P. Rubin, S. M. Schuetze, J. F. Eary et al., “Molecular targeting of platelet-derived growth factor B by imatinib mesylate in a patient with metastatic dermatofibrosarcoma protuberans,” Journal of Clinical Oncology, vol. 20, no. 17, pp. 3586–3591, 2002. View at Publisher · View at Google Scholar · View at Scopus
49. F. Pedeutour, J. M. Coindre, G. Nicolo, et al., “Response of metastatic dermatofibrosarcoma protuberans to imatinib mesylate,” Proceedings of the American Society of Clinical Oncology, vol. 23, abstract 3334, 2003.
50. W. Ruka, S. Falkowski, U. Grzesiakowska, et al., “The partial response of lung metastases arising from dermatofibrosarcoma protuberans after one month of imatinib mesylate therapy—a case report,” Nowotwory, vol. 53, no. 2, pp. 165–168, 2003. View at Scopus
51. S. V. Labropoulos, J. A. Fletcher, A. M. Oliveira, S. Papadopoulos, and E. D. Razis, “Sustained complete remission of metastatic dermatofibrosarcoma protuberans with imatinib mesylate,” Anti-Cancer Drugs, vol. 16, no. 4, pp. 461–466, 2005. View at Publisher · View at Google Scholar · View at Scopus
52. K. Mizutani, Y. Tamada, K. Hara et al., “Imatinib mesylate inhibits the growth of metastatic lung lesions in a patient with dermatofibrosarcoma protuberans,” British Journal of Dermatology, vol. 151, no. 1, pp. 235–237, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
53. G. A. McArthur, G. D. Demetri, A. Van Oosterom et al., “Molecular and clinical analysis of locally advanced dermatofibrosarcoma protuberans treated with imatinib: imatinib target exploration consortium study B2225,” Journal of Clinical Oncology, vol. 23, no. 4, pp. 866–873, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
54. M. C. Heinrich, H. Joensuu, G. D. Demetri et al., “Phase II, open-label study evaluating the activity of imatinib in treating life-threatening malignancies known to be associated with imatinib- sensitivetyrosine kinases,” Clinical Cancer Research, vol. 14, no. 9, pp. 2717–2725, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
55. P. Rutkowski, M. Van Glabbeke, C. J. Rankin et al., “Imatinib mesylate in advanced dermatofibrosarcoma protuberans: pooled analysis of two phase II clinical trials,” Journal of Clinical Oncology, vol. 28, no. 10, pp. 1772–1779, 2010. View at Scopus
56. P. Rutkowski, M. Dębiec-Rychter, Z. I. Nowecki et al., “Treatment of advanced dermatofibrosarcoma protuberans with imatinib mesylate with or without surgical resection,” Journal of the European Academy of Dermatology and Venereology, vol. 25, no. 3, pp. 264–270, 2011. View at Publisher · View at Google Scholar · View at PubMed
57. A. Gronchi, S. Stacchiotti, F. Pedeutour, et al., “Response to imatinib mesylate (IM) in fibrosarcoma (FS) arising in dermatofibrosarcoma protuberans (DFSP),” Journal of Clinical Oncology, vol. 26, supplement, 2008, abstract 10593.
58. D. Kérob, R. Porcher, O. Vérola et al., “Imatinib mesylate as a preoperative therapy in dermatofibrosarcoma: results of a multicenter phase II study on 25 patients,” Clinical Cancer Research, vol. 16, no. 12, pp. 3288–3295, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
59. R. B. West, B. P. Rubin, M. A. Miller et al., “A landscape effect in tenosynovial giant-cell tumor from activation of CSF1 expression by a translocation in a minority of tumor cells,” Proceedings of the National Academy of Sciences of the United States of America, vol. 103, no. 3, pp. 690–695, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
60. J. Y. Blay, H. El Sayadi, P. Thiesse, J. Garret, and I. Ray-Coquard, “Complete response to imatinib in relapsing pigmented villonodular synovitis/tenosynovial giant cell tumor (PVNS/TGCT),” Annals of Oncology, vol. 19, no. 4, pp. 821–822, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus